Received Oct 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | — | OT |
AECOPD 2/2 COVID infection; AECOPD 2/2 COVID infection; This is a spontaneous report received from a Lawyer and a Physician from legal division. A 49-year-old female patient received BNT162b2 (BNT162B2), on 23Mar2021 as dose 1, single (Batch/Lot number: unknown), on 13Apr2021 as dose 2, single (Batch/Lot number: unknown) and on 26Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 49 years, all intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Asthma-COPD overlap", start date: 12Nov2018 (unspecified if ongoing); "Back pain", start date: 30Jul2014 (unspecified if ongoing); "Hilar lymphadenopathy", start date: 30Jul2014 (unspecified if ongoing); "Lymphadenopathy", start date: 30Jul2014 (unspecified if ongoing); "Major depression", start date: 10Sep2016 (unspecified if ongoing); "Mixed anxiety depressive disorder", start date: 10Sep2016 (unspecified if ongoing); "Pelvic inflammatory disease", start date: 27Aug2011 (unspecified if ongoing); "post-traumatic stress disorder", start date: 08Jan2021 (unspecified if ongoing); "Seasonal allergic rhinitis", start date: 21Sep2019 (unspecified if ongoing); "Sinus Problem" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (hospitalization, medically significant), COVID-19 (hospitalization, medically significant), outcome "unknown" and all described as "AECOPD 2/2 COVID infection". The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Anxiety disorder; Asthma-COPD overlap syndrome; Back pain; Hilar lymphadenopathy; Lymphadenopathy; Major depression; Pelvic inflammatory disease; Post-traumatic stress disorder; Seasonal allergic rhinitis; Sinus pain